Martingale Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $13M | Buy |
16,861
+7,097
| +73% | +$5.43M | 0.33% | 105 |
|
|
2025
Q4 | $7.54M | Buy |
+9,764
| New | +$6.63M | 0.19% | 127 |
|
|
2025
Q3 | – | Sell |
-2,598
| Closed | -$1.36M | – | 827 |
|
|
2025
Q2 | $1.36M | Sell |
2,598
-8,998
| -78% | -$5.02M | 0.03% | 396 |
|
|
2025
Q1 | $7.35M | Sell |
11,596
-8,612
| -43% | -$5.92M | 0.19% | 132 |
|
|
2024
Q4 | $14.4M | Sell |
20,208
-1,503
| -7% | -$1.26M | 0.35% | 106 |
|
|
2024
Q3 | $22.8M | Sell |
21,711
-4,472
| -17% | -$4.98M | 0.52% | 70 |
|
|
2024
Q2 | $27.5M | Sell |
26,183
-3,279
| -11% | -$3.18M | 0.6% | 57 |
|
|
2024
Q1 | $28.4M | Sell |
29,462
-3,320
| -10% | -$3.16M | 0.57% | 65 |
|
|
2023
Q4 | $28.8M | Sell |
32,782
-1,473
| -4% | -$1.21M | 0.59% | 59 |
|
|
2023
Q3 | $28.2M | Sell |
34,255
-2,097
| -6% | -$1.65M | 0.59% | 60 |
|
|
2023
Q2 | $26.1M | Sell |
36,352
-2,000
| -5% | -$1.54M | 0.51% | 77 |
|
|
2023
Q1 | $31.5M | Sell |
38,352
-527
| -1% | -$397K | 0.61% | 57 |
|
|
2022
Q4 | $28.1M | Sell |
38,879
-3,627
| -9% | -$2.68M | 0.55% | 72 |
|
|
2022
Q3 | $29.3M | Sell |
42,506
-1,829
| -4% | -$1.15M | 0.58% | 63 |
|
|
2022
Q2 | $26.2M | Sell |
44,335
-3,545
| -7% | -$2.3M | 0.48% | 77 |
|
|
2022
Q1 | $33.4M | Sell |
47,880
-3,422
| -7% | -$2.16M | 0.5% | 79 |
|
|
2021
Q4 | $32.4M | Sell |
51,302
-3,054
| -6% | -$1.88M | 0.41% | 95 |
|
|
2021
Q3 | $32.9M | Sell |
54,356
-10,813
| -17% | -$6.71M | 0.43% | 97 |
|
|
2021
Q2 | $36.4M | Sell |
65,169
-3,192
| -5% | -$1.62M | 0.42% | 93 |
|
|
2021
Q1 | $32.3M | Buy |
68,361
+4,498
| +7% | +$2.19M | 0.37% | 102 |
|
|
2020
Q4 | $30.9M | Buy |
63,863
+10,729
| +20% | +$5.79M | 0.35% | 104 |
|
|
2020
Q3 | $29.7M | Buy |
53,134
+12,946
| +32% | +$7.85M | 0.36% | 104 |
|
|
2020
Q2 | $25.1M | Buy |
+40,188
| New | +$22.8M | 0.3% | 114 |
|
|
2019
Q3 | – | Sell |
-1,303
| Closed | -$408K | – | 1045 |
|
|
2019
Q2 | $408K | Sell |
1,303
-1
| -0.1% | -$333 | ﹤0.01% | 917 |
|
|
2019
Q1 | $536K | Buy |
+1,304
| New | +$537K | 0.01% | 880 |
|
|
2018
Q1 | – | Sell |
-603
| Closed | -$227K | – | 978 |
|
|
2017
Q4 | $227K | Sell |
603
-600
| -50% | -$243K | ﹤0.01% | 912 |
|
|
2017
Q3 | $538K | Buy |
+1,203
| New | +$572K | 0.01% | 828 |
|
|
2017
Q1 | – | Sell |
-4,615
| Closed | -$1.7M | – | 979 |
|
|
2016
Q4 | $1.7M | Sell |
4,615
-310
| -6% | -$118K | 0.02% | 589 |
|
|
2016
Q3 | $1.98M | Buy |
4,925
+50
| +1% | +$20.1K | 0.03% | 513 |
|
|
2016
Q2 | $1.7M | Buy |
4,875
+495
| +11% | +$191K | 0.03% | 359 |
|
|
2016
Q1 | $1.58M | Buy |
4,380
+140
| +3% | +$57.7K | 0.03% | 370 |
|
|
2015
Q4 | $2.3M | Buy |
4,240
+500
| +13% | +$271K | 0.05% | 290 |
|
|
2015
Q3 | $1.74M | Buy |
3,740
+1,740
| +87% | +$934K | 0.04% | 333 |
|
|
2015
Q2 | $1.02M | Buy |
2,000
+925
| +86% | +$451K | 0.02% | 508 |
|
|
2015
Q1 | $486K | Buy |
1,075
+300
| +39% | +$127K | 0.01% | 711 |
|
|
2014
Q4 | $318K | Buy |
+775
| New | +$305K | 0.01% | 770 |
|
Other funds holding REGN
VCM
N
Martingale Asset Management's REGN Position: Q1 2026 in Review
Martingale Asset Management increased its Regeneron Pharmaceuticals (REGN) stake by 73% in Q1 2026, buying an estimated $5.43M and bringing the position to 16,861 shares worth $13M. The position accounts for 0.33% of the portfolio, ranked #105.
Martingale Asset Management first reported a position in REGN in Q4 2014 and has held it in 36 quarters since. The position peaked at $36.4M in Q2 2021. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.
- Martingale Asset Management held 16,861 shares of Regeneron Pharmaceuticals worth $13M as of Q1 2026.
- Martingale Asset Management bought 7,097 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $5.43M.
- Regeneron Pharmaceuticals made up 0.33% of Martingale Asset Management's portfolio in Q1 2026, its #105 holding.
- Martingale Asset Management first reported a position in Regeneron Pharmaceuticals in Q4 2014 and has held it in 36 quarters since.
- Martingale Asset Management's Regeneron Pharmaceuticals position peaked at $36.4M in Q2 2021.
- 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.
Based on Martingale Asset Management's 13F filing for Q1 2026, filed 13 May 2026.